In turn, translation of new discoveries into personalized therapies for individuals and
populations is grounded in extending observations from clinical trials to therapeutic …

Foreword Waldman & Terzic advances in our understanding of the molecular mechanisms
contributing to pathogenesis have yielded an abundance of drug targets to individualize …

The current drug discovery paradigm is long, costly, and prone to failure. For projects in
early development, lack of efficacy in Phase II is a major contributor to the overall failure rate …

A greater understanding of disease biology processes, the opportunity to develop targeted
drugs leading to further improved patient outcomes and technology advances, as well as …

Personalized medicine is based on: 1) improved clinical or non-clinical methods (including
biomarkers) for a more discriminating and precise diagnosis of diseases; 2) targeted …

Biomarkers are important tools for identifying and stratifying diseases, predicting their
progression and determining the effectiveness, safety, and doses of therapeutic …

Despite an increased investment in research and development, there has been a steady
decline in the number of drugs brought to market over the past 40 years. The tools of …

Considerable variety in how patients respond to treatments, driven by differences in their
geno-and/or phenotypes, calls for a more tailored approach. This is already happening, and …

Gene-based molecular diagnostics is changing the practice of medicine and will continue to
do so for the foreseeable future. The major underlying principle of these diagnostic tests is …

Today, the practice of medicine remains largely empirical. Physicians generally rely on
matching patterns in patient history, symptoms, and laboratory data to make the diagnosis …